首页 | 本学科首页   官方微博 | 高级检索  
     


Synthesis and biological activity of tachykinin analogs containing the adamantane moiety
Authors:Daniela Pinzani   Anna Maria Papini   Mario Chelli   Mauro Ginanneschi   Carlo Alberto Maggi   Riccardo Patacchini   Laura Quartara  Gianfranco Rapi
Affiliation:(1) Department of Organic Chemistry "lsquo"Ugo Schiff"rsquo", Italy;(2) Centro di Studio sulla Chimica e la Struttura dei Composti Eterociclici e loro Applicazioni of the C.N.R., c/o University of Florence, via Gino Capponi 9, I-50121 Florence, Italy;(3) Menarini S.r.l. Pharmaceuticals, via Sette Santi 3, I-50131 Florence, Italy
Abstract:Summary The adamantane moiety was introduced in the tachykinin NK2 receptor-selective agonist [beta-Ala8]-NKA(4–10) (H-Asp-Ser-Phe-Val-beta-Ala-Leu-Met-NH2, MEN 10210) and in different positions of the NK2 receptor antagonist MEN 10376 (H-Asp-Tyr-d-Trp-Val-d-Trp-d-Trp-Lys-NH2) in order to investigate how this substitution affects their biological activity at tachykinin NK1, NK2 and NK3 receptors. 1-Adamantaneacetic acid (1-Ada-CH2COOH) was directly conjugated in the solid phase as the preformed OBt active ester to the N-terminal position of MEN 10210, obtaining MEN 10586 (1-Ada-CH2CO-Asp-Ser-Phe-Val-beta-Ala-Leu-Met-NH2). The Pfp ester of adamantaneacetic acid (1) was prepared and used for the acylation of the N-terminal position of MEN 10376, yielding MEN 10606 (1-Ada-CH2CO-Asp-Tyr-d-Trp-Val-d-Trp-d-Trp-Lys-NH2). Compound 1 was then used to obtain the building block Fmoc-Lys(1-Ada-CH2CO)-OH as a modified amino acid for the synthesis of MEN 10818 [H-Asp-Tyr-d-Trp-Val-d-Trp-d-Trp-Lys(1-Ada-CH2CO)-NH2]. In order to investigate the biological activity of the peptide bearing the adamantane group together with the free N-terminal amino function, we synthesised MEN 10676 [H-Asp(O-2-Ada)-Tyr-d-Trp-Val-d-Trp-d-Trp-Lys-NH2] using Fmoc-Asp(O-2-Ada)-OH, in which 2-adamantanole was the protecting group of the aspartate beta-COOH moiety during the peptide synthesis and survived the final peptide cleavage and deprotection carried out under controlled conditions. MEN 10586 showed an agonist activity comparable to that of the parent compound MEN 10210 at NK1 and NK2 receptors of guinea pig ileum, rabbit isolated pulmonary artery and hamster isolated trachea preparations, while it showed a 25-fold higher agonist activity at NK3 receptors of rat isolated portal vein. The three modified antagonist analogs displayed similar or reduced affinity at NK1, NK2 and NK3 receptors as compared to MEN 10376. The drop was particularly evident (>2 log units) at the NK2 receptors of the rabbit isolated pulmonay artery.
Keywords:Adamantane derivatives  Tachykinins  NK2 antagonists  NK2 agonists  Pentafluorophenyl ester
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号